In type 2 diabetes, additional therapies are needed over time to maintain acceptable glycemic control ([@B1]--[@B3]). When lifestyle measures and oral antihyperglycemic agents are no longer sufficient, the addition of basal insulin optimized by systematic titration of dosage can restore glycated hemoglobin (HbA~1c~) to 7.0% for 50--60% of people with type 2 diabetes ([@B2],[@B4],[@B5]). However, some people do not initially achieve this glycemic target with basal insulin plus oral therapy, and others experience later deterioration of control ([@B6]--[@B9]). Further therapy, especially for postprandial hyperglycemia, is then needed. A traditional option has been to add one or more injections of prandial insulin ([@B10]), but adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) is a recently proposed alternative that may improve glycemic control without additional weight gain and, perhaps, with less hypoglycemia. Drugs of this class have effects that complement those of basal insulin; they potentiate endogenous insulin responses to hyperglycemia, suppress inappropriately elevated glucagon secretion, and favor weight loss by promoting satiety ([@B11],[@B12]). In addition, GLP-1RAs can slow gastric emptying, further blunting postprandial hyperglycemia. However, slowing of gastric emptying appears to be greater with short-acting than with long-acting GLP-1RAs ([@B13]), possibly related to the observation that, with time, continuous exposure of GLP-1 leads to a reduction in its effect on gastric emptying ([@B14]).

Lixisenatide is a novel GLP-1RA that, like other drugs of its class, has demonstrated significant improvements in glycemic control, low rates of hypoglycemia, and a beneficial effect on weight ([@B15]--[@B17]). Lixisenatide taken once daily ([@B15]) improves HbA~1c~ levels by reducing fasting plasma glucose (FPG) and has robust postprandial glucose (PPG) effects ([@B18],[@B19]). Lixisenatide was granted marketing authorization by the European Medicines Agency in February 2013 ([@B20]). The objective of this study was to examine the efficacy and safety of adding once-daily lixisenatide to established basal insulin therapy (dosage maintained except for the avoidance of hypoglycemia), alone or together with metformin, in people with long-duration type 2 diabetes and inadequate glycemic control.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Study design {#s2}
------------

This was a randomized, placebo-controlled, two-arm, parallel-group, double-blind phase III study with a 24-week treatment period. It was conducted in 111 centers in 15 countries (Brazil, Canada, Chile, Egypt, France, Germany, India, Italy, Republic of Korea, Mexico, Puerto Rico, Russian Federation, Turkey, U.K., and U.S.) from July 2008 to February 2011 ([clinicaltrials.gov](http://clinicaltrials.gov), NCT00715624). It was approved by the institutional review boards or ethics committees of the participating centers and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All participants gave written informed consent. An independent Data Monitoring Committee provided an ongoing review of unmasked efficacy and safety data, and an Allergic Reaction Assessment Committee (ARAC) and a Cardiovascular Event Adjudication Committee reviewed masked events.

Participants {#s3}
------------

Adults with type 2 diabetes diagnosed ≥1 year at the time of screening were eligible if they had used a basal insulin regimen for ≥3 months with a stable dose (±20%) ≥30 units/day for ≥2 months before screening and had HbA~1c~ = 7--10%. Candidates using metformin must have taken a stable dose of at least 1.5 g/day (South Korea, at least 1.0 g/day) for at least 3 months before screening. Exclusion criteria included FPG \>13.9 mmol/L (250 mg/dL); BMI ≤20.0 kg/m^2^; weight change \>5.0 kg over the 3 months before screening; history of unexplained pancreatitis, end-stage renal disease, or allergic reaction to any GLP-1RA in the past; or pregnancy.

Randomization, masking, and dosing {#s4}
----------------------------------

Eligible participants were centrally randomized and entered a 24-week, double-blind treatment period ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)). Lixisenatide or placebo was packaged into treatment kits and labeled with a number. Treatment numbers were allocated on day 1, using an interactive voice-response system, after completion of the baseline assessment. Investigators did not have access to the randomization code. In addition, reviews by the ARAC members were all blinded. Lixisenatide and placebo treatments were indistinguishable, but the injected volume differed according to the titration step (or maintenance period) and the injected volume was unblinded. Randomization was stratified by HbA~1c~ (\<8.0 and ≥8.0% \[\<64 and ≥64 mmol/mol\]) and metformin use at screening (yes or no). Randomization was in a 2:1 ratio to once-daily lixisenatide or placebo in a two-step dose-increase regimen (10 μg for 1 week, 15 μg for 1 week, and then 20 μg if tolerated). Lixisenatide or placebo was given subcutaneously within 1 h before the morning meal. If used at enrollment, metformin was continued at a stable dose throughout the study. In general, basal insulin dosage was to remain relatively stable (±20%) throughout the study. However, if HbA~1c~ was ≤7.5% (≤58 mmol/mol) at screening, the daily dosage of basal insulin was initially reduced by 20% at randomization to limit the risk of hypoglycemia and thereafter progressively increased between weeks 4 and 12 to the dosage used at the screening visit, unless prevented by the occurrence of hypoglycemia. After week 12, no further dose adjustments of basal insulin were to be made except for reductions in response to hypoglycemia. Rescue therapy, preferably with rapid-acting insulin, was permitted if FPG was \>15.0 mmol/L (270 mg/dL) any time between randomization and week 8, FPG was \>13.3 mmol/L (240 mg/dL) from week 8 through 12, and FPG was \>11.1 mmol/L (200 mg/dL) or HbA~1c~ \>8.5% from week 12 through 24.

Efficacy and safety measurements {#s5}
--------------------------------

The primary end point was the change in HbA~1c~ from randomization to week 24. Secondary measures included the percentage of patients attaining HbA~1c~ \<7.0 or ≤6.5% (\<53 or ≤48 mmol/mol); change from baseline in FPG, body weight, seven-point self-measurement of plasma-referenced glucose (SMPG), and 2-h PPG after a standardized meal and glucose excursion (2-h PPG levels minus plasma glucose levels 30 min prior to the standardized meal before study drug administration); daily basal insulin dosage; and percentage of participants requiring rescue therapy.

Samples for FPG and HbA~1c~ were measured at a certified (National Glycohemoglobin Standardization Program Level 1; Covance) central laboratory by high-performance liquid chromatography. Participants performed SMPG at least once a day, and, in addition, seven times over a 24-h period (before and 2 h after each meal and at bedtime) before randomization, and during the week before each subsequent visit. Additional tests were performed for symptoms consistent with hypoglycemia. Insulin dose, SMPG, and symptoms of hypoglycemia were recorded in diaries for review by study personnel. All participants ingested a standardized liquid breakfast meal (Ensure Plus drink; Abbott; 600 kcal with 54% carbohydrate, 17% protein, and 29% fat, consumed within a 10-min period, 30 min after study drug administration) before randomized treatment and at week 24 or last visit. Body weight was recorded at screening, randomization, and thereafter at weeks 4, 6, 8, 12, and 24 (or last visit); clinical histories were recorded at randomization and at each subsequent visit.

Safety was assessed by review of adverse events (AEs), symptomatic hypoglycemia, and clinical laboratory data. Laboratory tests were performed for hematology, creatinine, microalbuminuria, pregnancy (in females of childbearing potential), and serum chemistry (including amylase, lipase, lipoproteins, and calcitonin). The status and concentration of antilixisenatide antibodies were determined using highly sensitive surface plasmon resonance technology (Biacore, Uppsala, Sweden) at baseline and at weeks 2, 4, and 24.

Statistical analysis {#s6}
--------------------

All efficacy end points were assessed for participants who received one or more doses of the allocated treatment and had a measurement at baseline (randomization) and at least one on-treatment measurement of any primary and secondary efficacy end point (modified intent-to-treat population). Data obtained after rescue therapy were excluded from the efficacy analyses. The safety population consisted of all randomized individuals who received at least one dose of the investigational product. The primary efficacy end point was analyzed using ANCOVA with treatment groups (lixisenatide and placebo), randomization strata and country as fixed effects, and baseline HbA~1c~ as a covariate. Superiority of lixisenatide compared with placebo was assessed based on the predefined primary analysis of the least squares (LS) mean changes from baseline to week 24 in HbA~1c~. The sample size/power calculation based on this end point estimated that enrollment of 300 and 150 participants in the lixisenatide and placebo arms, respectively, would provide 86% power of detecting a 0.4% difference between treatments in change of HbA~1c~ from baseline, with a two-sided test at the 5% significance level and a common SD of 1.3%. The 2:1 randomization ratio was chosen to provide sufficient participant exposure to lixisenatide for safety evaluation in the context of the whole phase 3 development program, as is required for regulatory review. For descriptive purposes, unadjusted mean values at distinct time points were calculated for the as-observed population, including all values available, even for individuals lacking data at baseline or week 24. Data for all continuous secondary efficacy end points were analyzed by a similar ANCOVA model, with the corresponding baseline value as a covariate. All categorical efficacy parameters were analyzed using a Cochran-Mantel-Haenszel method with adjustment for the stratification variables. In case of missing week-24 measurements, LS mean change was calculated with last observation carried forward (LOCF). A sample size of at least 450 participants (300 for lixisenatide and 150 for placebo) provided a power of 96% (or 86%) to detect a treatment difference of 0.5% (or 0.4%) in the absolute change in HbA~1c~ from baseline to week 24. This assumed a common SD of 1.3% with a two-sided 5% significance level. Summaries and statistical analyses were generated using SAS version 9.1.3 (SAS, Carey, NC) or higher.

RESULTS {#s7}
=======

Participant flow and characteristics {#s8}
------------------------------------

Of 879 candidates screened, 496 eligible participants were randomized and 495 received treatment ([Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)). Baseline demographics and characteristics of participants were balanced between the two groups, although no formal statistical comparison between groups was conducted ([Table 1](#T1){ref-type="table"}). Overall, mean duration of diabetes was 12.5 years, mean duration of basal insulin use was 3.1 years, mean insulin dosage was 55 units daily, and mean HbA~1c~ at baseline was 8.4% ([Table 1](#T1){ref-type="table"}). Basal insulin at entry was glargine (50%) or human neutral protamine Hagedorn (NPH; 40%) in most cases. Most participants (79%) were taking metformin.

###### 

Demographics and patient characteristics\*
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Responses to therapy {#s9}
--------------------

### HbA~1c~. {#s10}

Mean HbA~1c~ (±SD) declined from 8.4 ± 0.9% at randomization to 7.8 ± 1.2% at 24 weeks in the lixisenatide group and from 8.4 ± 0.8 to 8.1 ± 1.2% in the placebo group (LS mean change difference --0.4% \[95% CI --0.6 to --0.2\]; *P* = 0.0002) ([Fig. 1*A*](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). A higher percentage of participants treated with lixisenatide versus placebo had HbA~1c~ \<7% at week 24 (28.3 vs. 12.0%; *P* \< 0.0001). Similarly, the percentage with HbA~1c~ ≤6.5% at 24 weeks was higher with lixisenatide versus placebo (14.5 vs. 3.8%; *P* = 0.0003) ([Table 2](#T2){ref-type="table"}).

![Clinical responses to therapy from baseline to week 24 and end point with LOCF. *A*: Mean HbA~1c~ (%) by visit. *B*: Mean FPG (mmol/L) by visit. *C*: Mean change in body weight (kg) from baseline by visit. *D*: Mean daily basal insulin dose (units/day) by visit. Values are all mean ± SE, for the modified intent-to-treat population. All analyses excluded measurements after the introduction of rescue medication and/or after treatment cessation plus 3 days. For week 24 (LOCF), the analysis included measurements obtained up to 3 days after the last dose of study drug.](2489fig1){#F1}

###### 

Clinical responses to therapy

![](2489tbl2)

### FPG. {#s11}

Mean FPG decreased slightly more initially with lixisenatide than placebo, but by week 24, there was no difference between treatments ([Fig. 1*B*](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

### Body weight. {#s12}

Body weight decreased by 1.8 kg with lixisenatide and 0.5 kg with placebo between randomization and week 24 (LS mean change −1.3 kg; *P* \< 0.0001) ([Fig. 1*C*](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

### Insulin dose. {#s13}

Daily basal insulin dosage was similar in the treatment groups at randomization. Dosage change by week 24 was --5.6 units/day with lixisenatide versus --1.9 units/day with placebo (LS mean change --3.7 units/day; *P* = 0.012) ([Fig. 1*D*](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

### SMPG profiles. {#s14}

Mean seven-point values were 10.7 and 10.6 mmol/L at randomization and 9.4 and 10.2 mmol/L on treatment with lixisenatide and placebo, respectively (LS mean difference −0.9 mmol/L; *P* \< 0.0001) ([Table 2](#T2){ref-type="table"}). Mean seven-point SMPG was lower throughout the day during treatment with lixisenatide compared with placebo ([Fig. 2](#F2){ref-type="fig"}). The greatest LS mean difference was seen at 2 h postbreakfast (--2.4 mmol/L \[--43 mg/dL\]) and the smallest prebreakfast (--0.3 mmol/L \[--5 mg/dL\]).

![Mean seven-point SMPG (mmol/L). Mean ± SE seven-point SMPG (mmol/L) at baseline and week-24 LOCF in the modified intent-to-treat population for basal insulin + lixisenatide (*A*) and basal insulin + placebo (*B*).](2489fig2){#F2}

### Standardized meal study. {#s15}

Mean 2-h PPG declined from 16.4 mmol/L at randomization to 11.0 mmol/L at week 24 in the lixisenatide group and from 15.9 to 14.7 mmol/L in the placebo group (LS mean difference −3.8 mmol/L; *P* \< 0.0001) ([Table 2](#T2){ref-type="table"} and [Supplementary Fig. 3*A*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)). The PPG excursion was similarly reduced for lixisenatide versus placebo (LS mean difference −3.8; *P* \< 0.0001) ([Table 2](#T2){ref-type="table"} and [Supplementary Fig. 3*B*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)).

### Rescue therapy. {#s16}

Rescue therapy with rapid-acting insulin or increase of basal insulin of \>20% was required by 19 (6%) participants assigned to lixisenatide and 12 (7%) participants receiving placebo (*P* = 0.540).

Hypoglycemia {#s17}
------------

Symptomatic documented hypoglycemia of \<3.3 mmol/L (60 mg/dL) was reported by 26.5% of participants using lixisenatide versus 21.0% with placebo (*P* = 0.174) ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)). Most events were diurnal and occurred during the first weeks of treatment. Four individuals in the lixisenatide group each experienced a single severe hypoglycemic event; a missed or delayed meal was reported for two of these participants.

Other AEs {#s18}
---------

A total of 73.5% of participants experienced at least one treatment-emergent AE with lixisenatide versus 68.3% with placebo ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2454/-/DC1)). AEs led to discontinuation for 7.6% in the lixisenatide group and 4.8% from the placebo group. The most common symptoms reported in lixisenatide-treated patients were gastrointestinal, mainly nausea or vomiting. Most reports of nausea occurred in the first 2 months of treatment in both groups. Injection site reactions were reported by the investigator for four participants (1.2%) in the lixisenatide group and one (0.6%) in the placebo group; none of these were considered severe by the investigator, and no participant discontinued as a result. The frequency of events adjudicated as allergic reactions by the ARAC was 1.5% in the lixisenatide group and 1.8% in the placebo group. Three events were considered by the ARAC to be possibly related to the treatment: two events in the lixisenatide group, reported by investigators as "allergic reaction," which rapidly improved after treatment with oral diphenhydramine (both events were adjudicated as low grade \[1°\] anaphylaxis), and one in the placebo group (severe tongue edema, treated with antihistamines and steroids, adjudicated by the ARAC as angioedema grade 4). Approximately 70% of participants were antilixisenatide antibody positive at week 24; of the antibody-positive participants, 70% had an antibody concentration below the limit of quantification. At week 24, there were no substantial differences in the reduction from baseline in HbA~1c~ levels or on the treatment-emergent AE profile between the antibody-positive and antibody-negative populations. No significant changes in heart rate or blood pressure occurred in either group, and no confirmed cases of acute pancreatitis were reported. No participants in the lixisenatide group had a calcitonin value ≥50 ng/L. One participant in the lixisenatide group died suddenly at home on day 25. This event was assessed at autopsy as sudden cardiac death and deemed not to be treatment related by the investigator.

CONCLUSIONS {#s19}
===========

This study demonstrated statistically and clinically significant improvements of glycemic control after adding once-daily lixisenatide to prior treatment with basal insulin with or without metformin in type 2 diabetes. The dosage of basal insulin was meant to be relatively constant to test the effect of lixisenatide itself, which resulted in reductions in HbA~1c~ by 0.7% from a baseline of 8.4%, and 0.4% more than placebo, despite lower insulin doses to minimize the risk of hypoglycemia. A corresponding improvement of SMPG profile values accompanied treatment with lixisenatide; the mean placebo-adjusted reduction was 0.9 mmol/L. Both the SMPG profiles and a standardized breakfast test showed a prominent glucose reduction after the first meal of the day. Moreover, body weight decreased significantly after lixisenatide treatment relative to placebo.

Several features of the study design require comment. First, by enrolling participants with relatively poor glycemic control despite using basal insulin and oral therapy, the study addressed a population for which improving glycemic control may be expected to be difficult. For comparison, in the 4T study, a year of treatment with titrated basal insulin therapy (insulin detemir once or twice daily; median dosage = 42 units daily) led to a mean HbA~1c~ of 7.6% in a previously insulin-naive population ([@B21]). Adding three prandial injections of rapid-acting insulin to basal insulin for an additional 2 years allowed most (63%) of these patients to attain HbA~1c~ ≤7.0%, but with significant weight gain and hypoglycemia as unwanted effects ([@B22]). The population in the current study entered with a mean HbA~1c~ of 8.4% after taking basal insulin for an average of \>3 years at a mean dosage of 55 units daily, and thus potentially presented an even more significant challenge for restoring glycemic control. Second, the study was designed to minimize changes of the type, timing, and dosage of insulin used to assess the effects of lixisenatide itself. Hence, the full potential of the combination of basal insulin with lixisenatide was not tested. Although more than twice as many participants attained HbA~1c~ \<7.0% with lixisenatide as with placebo (28 vs. 12%), over two-thirds of them did not reach this goal. Further titration of basal insulin dosage in combination with lixisenatide might have allowed a greater number of participants to reach HbA~1c~ \<7.0%.

The favorable responses of glycemic control and weight just described are in keeping with previous studies of lixisenatide, in which a single daily dose taken in the morning improved postprandial and day-long glycemic control while limiting body weight gain or even reducing weight ([@B18],[@B19]). In addition, the safety measures in this study are consistent with prior observations ([@B18],[@B19]). No excess of serious AEs was observed. The nonsevere AEs included, as in other studies of lixisenatide and other GLP-1RAs, mainly gastrointestinal symptoms (which were usually transitory) and a 1--2% incidence of injection site reactions ([@B18],[@B19],[@B23]).

The findings reported here add to the limited information currently available on the effects of combining a GLP-1RA with basal insulin for treatment of type 2 diabetes. Other studies have shown improved glycemic control with little or no weight gain after initiating combined therapy with exenatide ([@B24]--[@B27]). In a 30-week, randomized study of twice-daily exenatide added to basal insulin (with vigorous titration) with or without metformin and/or pioglitazone ([@B28]), exenatide reduced HbA~1c~ by --0.7% and body weight (by --2.7 kg relative to placebo), and insulin dose was increased in both groups. Recently, a 26-week randomized study of combining liraglutide with basal insulin has been reported ([@B28]), in which the inverse order of the introduction of drugs was tested. That is, patients who did not attain HbA~1c~ \<7.0% despite treatment with liraglutide and oral agents were randomized to add titrated basal insulin or to continue liraglutide without insulin. Adding basal insulin to liraglutide led to a greater additional reduction of HbA~1c~ (--0.5%) than that seen with continued liraglutide without basal insulin. No weight gain was observed in either randomized group, and the reduction was 0.8 kg more with the continuation of liraglutide alone than when insulin was added. In an earlier, 24-week, placebo-controlled study in an Asian population, lixisenatide added to basal insulin and oral therapy ([@B19]) resulted in a reduction in HbA~1c~ of −0.9% versus placebo. Weight increased by 0.1 kg with placebo and decreased by 0.4 kg (*P* = 0.086) with lixisenatide. The HbA~1c~ and weight differences relative to placebo in the current study (--0.4% HbA~1c~ and --1.3 kg) are consistent with findings in the other studies, and collectively all the studies support the efficacy and safety of combining a GLP-1RA with basal insulin.

Limitations of the present placebo-controlled study include the lack of comparison of lixisenatide with other possible ways of intensifying treatment with basal insulin and metformin. Further studies are needed to directly compare lixisenatide with exenatide or liraglutide in combination with basal insulin, and also to determine the relative efficacy and safety of lixisenatide versus prandial insulin added to basal insulin in similar populations. A direct comparison of glycemia, body weight, and other effects of adding lixisenatide with those of adding a DPP-4 inhibitor or another newer oral therapy would also be of interest. Finally, the long-term effects of this treatment approach may be clarified by the controlled extension of the current study and by other long-term studies.

In summary, addition of once-daily lixisenatide to basal insulin, with or without metformin and with insulin dosage kept stable except to limit hypoglycemia, resulted in a significant improvement of HbA~1c~, PPG level after a breakfast meal, and seven-point glucose profiles. Additionally, body weight was reduced. Hypoglycemia and nausea were increased compared with placebo, although there was no excess of serious AEs. These favorable findings in a challenging clinical population suggest that addition of once-daily lixisenatide to prior treatment with basal insulin offers an alternative to rapid-acting insulin or other agents to improve glycemic control in this setting and deserves further study.
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